Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2003

View Archived Issues

Artemin potentially useful for neuropathic pain

Improved penile erection in rats treated with ABT-724

SB-399885: cognitive effects in rats

New approach to treatment of postmenopausal women

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: ACE BioSciences

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Arpida

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Artesian Therapeutics

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Avontec

Evidence of beneficial effects for CP-113818 in a preclinical model of AD

Nemifitide safe and effective in major depressive disorder

Antiangiogenic and antiproliferative effects described for AP-23573 in tumor cells

BioInvent and Xoma enter crosslicense agreement

NIH grant supports Bionomics research on epilepsy

Enrollment completed in STELLAR 3 pivotal trial of Xyotax

Progression-free survival prolonged in Avastin study in colorectal cancer

Expansion of Tranzyme and NeoGenesis collaboration

Enrollment completed in phase II study of Paxceed

Positive phase III topline results for Surfaxin in RDS

Pliva updates pipeline progress

Meiji Seika describes novel voltage-gated sodium channel blockers

New tachykinin NK1 antagonists and their use claimed by Kyorin team

Takeda researchers prepare and test new squalene synthase inhibitors

Sumitomo patent covers PAR2 inhibitors and their use in inflammatory disorders

New microbially produced antibiotic identified at Meiji Seika

Toray scientists present inhibitors of alpha4 integrin-mediated cell adhesion

Mutual recognition procedure completed for high-dose Symbicort Turbuhaler

Nebido receives approval in Finland

Approval to extend phase I trial of I.N.T.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...